The objective of the present research protocol, a cross-over, subject-blinded, clinical trial, is to correlate changes in brain activity with reduction in suicidal ideation in response to a single intramuscular dose of ketamine. While ketamine is increasingly used as a rapid, antidepressant agent, there is accumulating evidence of additional anti-suicidal properties that may be distinct from its effects on depression. This pilot study will be used to determine (1) whether specific electroencephalogram (EEG) findings are correlated with response of SI to intramuscular (IM) ketamine, and (2) the effectiveness of IM ketamine in the treatment of acute SI.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
0.5 mg/kg of body weight
IM injection of matching placebo
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Change in Auditory Mismatch Negativity (EEG)
Change in Mismatch Negativity (MMN) amplitude or latency from baseline up to one hour after injection.
Time frame: Baseline and One hour post injection
Change in Montgomery-Asberg Depression Rating Scale (MADRS) #10 (SI)
Change in MADRS #10 from baseline to 24 hours post-injection. Score range from 0-5, with higher score indicating higher severity of symptoms.
Time frame: Baseline and 24 hours post injection
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.